Keywords: gsk, defends, avandia, against, findings, cv, risk

GSK defends Avandia against findings of CV risk by ICES group

Article | 17 December 2007

Print This

Concerns about the cardiovascular safety of glitazone drugs were raised once again with the publication of the first population-based study ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in